Susan Axelby, 66, has been awarded a substantial payout from Allergan Ltd after developing cancer associated with her breast implants. Ms. Axelby, who opted for a double mastectomy in 1999 due to a family history of breast cancer, received implants from the company later that year. However, she faced persistent complications, leading to multiple surgeries.
In 2018, Ms. Axelby was diagnosed with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a form of non-Hodgkin’s lymphoma linked to certain implants, including those manufactured by Allergan. The implants were globally suspended in 2018, recalled in 2019, and are no longer used in the UK.
Sarah Moore, a partner at Leigh Day solicitors representing Ms. Axelby, highlighted ongoing risks for women who have received these implants despite their market withdrawal. Ms. Axelby’s legal claim against Allergan Ltd was settled in November 2023, with compensation awarded despite no admission of liability.
Ms. Axelby expressed relief at the settlement, emphasizing the significant impact of her diagnosis on her life. She stated, “I wanted to take legal action against Allergan to ensure accountability,” adding that it’s crucial for other women to be informed about potential risks associated with certain implants.
According to the UK government, most cases of BIA-ALCL are curable with early diagnosis and removal of implants and surrounding scar tissue, though additional treatments may be necessary in rare instances.
This settlement is noted as one of the first of its kind in the UK regarding BIA-ALCL and serves as a reminder of ongoing concerns surrounding breast implants and associated health risks.
Officials emphasize that there are currently no screening tests available for BIA-ALCL, and advise women to promptly consult their GP if they notice any unexpected changes in the size, shape, or feel of their breasts.
Sarah Moore, a partner at Leigh Day specializing in international claims, expressed satisfaction with achieving a settlement for Susan Axelby, hoping it brings closure following her challenging experience with Allergan implants.
Moore emphasized ongoing concerns for women with Allergan breast implants regarding the risk of developing BIA-ALCL, noting that while the risk is considered low, obstacles remain in obtaining timely diagnoses, particularly in the private healthcare sector.
Related topics:
